CEO Executive AssistantLeading a clinical-stage biotech company without commercial revenue is one of the most distinctive leadership contexts in any industry. There is no sales organization, no customer acquisition funnel, no revenue operations team. The company is entirely sustained by capital raised from investors against the expectation of future value created by scientific and clinical progress. Every dollar spent must be justified against a finite runway. Every relationship the CEO builds, with investors, partners, regulators, and the scientific community, either extends that runway or shortens it.
Clinical stage biotech CEO time management is not simply a personal productivity problem. It is a strategic question about where the CEO’s attention creates the most value for a company that has no revenue and unlimited demands on leadership time. Get the allocation right and the company raises capital, advances its programs, and attracts the partnerships that accelerate development. Get it wrong and the company runs out of money with a pipeline that should have succeeded.
This article examines the five primary time domains for a clinical-stage biotech CEO, how to allocate attention across them, and the discipline required to prevent any one domain from consuming disproportionate bandwidth.
Investor Relations as the Primary Commercial Function
The CEO Who Understands That IR Is the Business
In a commercial-stage pharma company, investor relations is one of many external functions competing for CEO time. In a clinical-stage biotech with no revenue, investor relations is the closest equivalent to running a commercial organization. Capital is the product. Investors are the customers. The CEO’s ability to build credibility, communicate the scientific and clinical thesis compellingly, and maintain investor confidence through the inevitable setbacks of drug development is what keeps the company alive.
This framing has practical implications for time allocation. Clinical-stage biotech CEOs who treat investor relations as a part-time function, delegated to an IR professional with minimal CEO involvement, consistently underperform in fundraising relative to CEOs who own the investor relationship personally. Major institutional investors, family offices, and crossover funds that provide growth-stage capital want to know and trust the CEO, not the IR coordinator.
The practical time allocation for investor relations in a clinical-stage biotech should be continuous and structured, not event-driven. Between financing rounds, the CEO should invest four to six hours per week in investor relationship maintenance: calls with existing investors to provide program updates, introductory calls with prospective investors identified by the IR team or board, and conference attendance that creates investor visibility. This cadence ensures that when the company enters a financing process, the investor base is already warm rather than being introduced to the CEO for the first time.
The Financing Process as an All-Consuming Period
When a financing process launches, whether a Series B, C, crossover round, or IPO preparation, the investor relations function expands to occupy a dominant share of CEO time for six to twelve weeks. This is unavoidable and should be planned for explicitly.
During a financing process, the CEO should expect to spend 60 to 70 percent of their working time on investor meetings, roadshow logistics, Q&A preparation, and data room management. The clinical and operational functions of the company must continue without the CEO as an active participant during this period. This requires that each direct report, including the CMO, CFO, and VP of Clinical Development, has full operational authority in their domain and clear criteria for what requires CEO decision-making versus what they should resolve independently.
CEOs who fail to pre-delegate during financing processes either underperform in the roadshow because they are distracted by internal operational matters, or allow clinical and operational functions to stall because they have retained decision-making authority they cannot exercise from a roadshow.
Investor Communication Discipline Between Rounds
The discipline of consistent investor communication between financing rounds is where many clinical-stage biotech CEOs underperform. Investors who receive quarterly program updates from the CEO, even brief written summaries of clinical progress, regulatory interactions, and upcoming milestones, are significantly more likely to participate in the next financing round than investors who hear from the company only when capital is needed.
The CEO who builds an investor update rhythm, whether monthly for lead investors and quarterly for the broader investor base, is investing time that will return multiples during the next financing process.
Clinical Development Oversight Without a Large Internal Team
The Lean Oversight Challenge
Clinical-stage biotechs rarely have the clinical development infrastructure of a large pharmaceutical company. A program in Phase 1 or Phase 2 may have one or two internal clinical leaders supported by a CRO and a small regulatory team. The CMO may be carrying clinical responsibilities across multiple programs with limited support. In the earliest stages, the CEO may have deep scientific involvement in programs that at a larger company would be several layers below CEO visibility.
This lean structure creates a specific time management challenge: the CEO needs to maintain enough clinical program fluency to represent the programs credibly to investors, regulators, and partners, while not becoming so operationally embedded in clinical execution that they crowd out the CMO and prevent delegation.
The appropriate CEO engagement with clinical development in a lean organization is structured and bounded. A weekly clinical program review with the CMO, reviewing enrollment progress, safety signals, protocol deviations, and site performance, gives the CEO the fluency they need without continuous involvement in operational details. Material decisions (protocol amendments, stopping rules, CRO contract modifications) warrant CEO visibility and input. Day-to-day clinical operations belong to the CMO and CRO.
Regulatory Interactions in the Pre-Approval Phase
For a clinical-stage company, IND-stage regulatory interactions are a core business function that requires CEO awareness even when the regulatory team manages execution. Type B meetings with FDA, responses to clinical holds, and the strategy decisions embedded in those interactions have direct implications for program timelines and capital requirements.
The CEO who is not sufficiently engaged with regulatory strategy in the IND stage will be caught off-guard when regulatory decisions create timeline changes that require investor communication, capital re-planning, or partnership strategy adjustments. Regulatory strategy is not a technical back-office function in a clinical-stage biotech: it is a fundamental input to the company’s business trajectory.
For clinical-stage companies managing KOL relationships alongside regulatory development, the intersection of scientific credibility and regulatory positioning is a CEO-level strategic function. See KOL time management for a detailed discussion of how to structure those relationships effectively.
Capital Allocation Decisions as the CEO’s Highest-Stakes Time Investment
Why Capital Allocation Requires CEO-Level Analysis
In a revenue-generating company, capital allocation decisions are shaped by multiple financial inputs: revenue, margins, operating leverage, and cash generation. In a clinical-stage biotech, capital allocation is simpler in structure but existentially consequential: the company has a finite cash balance, a defined set of programs requiring investment, and a runway that must be managed against clinical milestones that will determine future capital access.
Every capital allocation decision in a clinical-stage biotech is a bet on program prioritization, timeline, and probability of success. Investing fully in a Phase 2 program that is unlikely to reach a value-inflection data readout before the company runs out of capital is a strategic error that capital allocation analysis can reveal. Cutting programs prematurely to extend runway, when those programs were the scientific foundation of the company’s investment thesis, is an equally serious error in the other direction.
The CEO’s role in capital allocation is not to build the financial models (that is the CFO’s function) but to integrate scientific, clinical, regulatory, and investor signals into portfolio prioritization decisions that the financial models quantify but cannot make. This requires genuine intellectual engagement with the capital allocation question, protected from the operational demands that can crowd it out.
A monthly capital allocation review with the CFO, reviewing runway against milestone calendar and updated program probability assessments, is the minimum governance structure required. In periods when capital is tight (runway under 18 months) or when significant capital decisions are imminent (a new program investment or a program pause), that cadence should increase.
Runway Management as a Continuous CEO Responsibility
Runway management is not solely a CFO function. The CEO who does not have a constant, clear view of the company’s runway against the milestone calendar that drives future capital access is exposed to existential surprises. Clinical-stage biotechs that run out of capital before reaching a value-inflection milestone typically do so not because the data were bad, but because the capital planning assumptions were optimistic and the CEO did not correct them until it was too late.
The discipline of runway management requires the CEO to maintain a clear-eyed view of three things: the current cash balance and burn rate, the realistic timeline to the next value-inflection milestone, and the capital market environment for the type of financing the company will need next. When those three variables align favorably, the CEO should be accelerating the timeline to the financing process. When they are misaligned, the CEO should be taking action (program prioritization changes, cost management, partnership acceleration) before the misalignment becomes a crisis.
Business Development and Partnership Time Investment
BD as a Strategic Multiplier
For clinical-stage biotechs without commercial revenue, business development and strategic partnerships can provide capital, development resources, and commercial infrastructure that would otherwise require years of fundraising and organizational build-out. A collaboration agreement, licensing deal, or co-development partnership with a larger pharmaceutical company can simultaneously address multiple strategic needs.
The CEO is the primary BD relationship holder for a clinical-stage biotech. While a VP of Business Development or an investment bank may manage the process of identifying and screening opportunities, the relationships that create the foundation for serious partnership discussions operate at the CEO level. A business development counterpart at a large pharmaceutical company will not commit organizational attention to a partnership with a company whose CEO they have not assessed personally.
This creates a specific time allocation requirement: the CEO should invest in maintaining active relationships with business development and alliance management leaders at the five to ten companies most likely to be strategic partners for their programs. These relationships are maintained through conference attendance, targeted outreach at key clinical milestones, and periodic direct conversations that allow the CEO to understand the partner’s portfolio needs and position the company’s programs accordingly.
Prioritizing BD Engagement Against Clinical Development Timelines
BD engagement should be highest when the company’s clinical data most clearly support a partnering narrative. A company entering Phase 2 with Phase 1 safety and early efficacy data is in a better partnering position than a company mid-enrollment with no interim data. A company that has just reported positive Phase 2 results has maximum partnering leverage.
Clinical-stage biotech CEOs who plan their BD engagement calendar against their clinical data readout schedule, rather than pursuing partnership conversations continuously regardless of where the programs stand, use their time more effectively and create better partnership outcomes.
Protecting Scientific Credibility Without Getting Lost in the Science
The Scientific CEO’s Time Trap
Many clinical-stage biotech CEOs come from scientific or clinical backgrounds and bring genuine scientific expertise to their leadership roles. This expertise is a competitive advantage in investor meetings, FDA interactions, and KOL engagement. But it also creates a specific time management vulnerability: the scientifically trained CEO who allows their scientific interests to pull them into detailed laboratory, research, or clinical data review at the expense of the external-facing and strategic functions that only the CEO can perform.
Scientific credibility requires maintenance, not immersion. A well-designed weekly scientific briefing from the CSO or CMO, focused on the most material developments in the company’s programs and the competitive landscape, maintains the CEO’s scientific fluency without requiring operational involvement in scientific work.
For a comprehensive view of how pharma CEO support helps maintain the right CEO engagement level across both scientific and operational domains, the structural principles translate directly to the clinical-stage context.
External Scientific Engagement as a Strategic Investment
Conference presentations, scientific publications from the company’s programs, and participation in disease-area working groups or advisory boards all build the CEO’s scientific credibility with the external audiences that matter most. These are investments with long time horizons: a CEO who is known in the scientific community as a credible, knowledgeable contributor builds the reputation that attracts the best employees, the strongest KOL relationships, and the most sophisticated investors.
Time investment in external scientific engagement should be budgeted, not spontaneous. One to two major conference presentations per year, participation in two or three advisory boards or working groups in the relevant disease area, and engagement with the publications process for key data packages from the company’s programs are reasonable targets that maintain external scientific credibility without crowding out the CEO’s primary functions.
Conclusion: Clinical Stage Biotech CEO Time Management as Portfolio Management
Clinical stage biotech CEO time management is fundamentally a portfolio allocation problem. The CEO has a finite stock of time, attention, and energy. The demands on that stock, from investor relations, clinical oversight, capital allocation, business development, scientific credibility maintenance, and organizational leadership, all have legitimate claims. The discipline lies in allocating correctly across the portfolio rather than allowing any single domain to capture all available resources.
The most effective clinical-stage biotech CEOs treat their own attention as the company’s scarcest asset, apply the same rigor to personal time allocation that they apply to capital allocation, and build the organizational and administrative infrastructure that allows them to maintain that discipline under the continuous pressure of a resource-constrained, milestone-driven business.
The NIH’s National Center for Advancing Translational Sciences provides useful context on the clinical translation ecosystem that shapes the environment clinical-stage biotechs operate in, including the regulatory and scientific milestones that drive so many of the CEO’s time allocation decisions.
Companies led by CEOs who manage their attention with this level of intention consistently outperform those where CEO time is reactive and unstructured, not because the science is better, but because the leadership resources available to advance the science are deployed more effectively.
Related Reading
For further context, explore How Biopharma CEOs Manage Time During Merger and Acquisition Due Diligence and How Biosimilar Company CEOs Manage Time Across Development and Market Access.